Publication Characterization of clofazimine metabolites in humans by HPLC-electrospray mass spectrometry. Krishna D R, Mamidi R N, Hofmann U, et al. Arzneimittel-Forschung. 1997; 47 (3) : 303-6.
Publication In vitro activity of a new rifamycin derivative against Mycobacterium leprae. Dhople A M, Dimova V. Arzneimittel-Forschung. 1996; 46 (2) : 210-2.
Publication In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice. Dhople A M, Ibanez M A. Arzneimittel-Forschung. 1994; 44 (4) : 563-5.
Publication In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae. Dhople A M, Ibanez M A, Gardner G D. Arzneimittel-Forschung. 1993; 43 (3) : 384-6.
Publication Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine. Freerksen E, Seydel J K. Arzneimittel-Forschung. 1992; 42 (10) : 1243-5.
Publication In vitro and in vivo effects of N-methyl-3,5-dichloro-benzylamine hydrochloride on Mycobacterium leprae. Dhople A M, Strong L C, Meindl W, et al. Arzneimittel-Forschung. 1991; 41 (3) : 253-6.
Publication In vitro and in vivo experiments with the new inhibitor of mycobacterium leprae brodimoprim alone and in combination with dapsone. Seydel J K, Wempe E G, Rosenfeld M, et al. Arzneimittel-Forschung. 1990; 40 (1) : 69-75.
Publication A comparison of the bactericidal activity of a series of rifampicins against Mycobacterium leprae. Pattyn S R. Arzneimittel-Forschung. 1982; 32 (1) : 15-7.
Publication Activity of the combination of isoniazid, protionamide and dapsone against Mycobacterium leprae and some other mycobacteria. Pattyn S R, Portaels F, Van Loo G, et al. Arzneimittel-Forschung. 1981; 31 (12) : 2155-7.
Publication Multivariate analysis of the activity of rifamycins against rapidly growing Mycobacteria, to define an in vitro screening model for their activity against mycobacterium leprae. Pattyn S R, Hébrant F. Arzneimittel-Forschung. 1980; 30 (12) : 2099-103.
Publication A new analogous model for the detection and evaluation of chemotherapeutic products effective in leprosy. Freerksen E, Rosenfeld M. Arzneimittel-Forschung. 1972; 22 (8) : 1235-42.
Publication Antimicrobial activity of the leprostatic drug 3-(p-chloranilino)-10-(p-chlorphenyl-2,10-dihydro-2-(isopropylimino)-phenazine (G 30'320, B. 663). Vischer W A. Arzneimittel-Forschung. 1970; 20 (5) : 714-23.
Publication [Toxicology of the antileprosy drug 3-(para-chloranilino)-10-(para-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazine (G 30 320). Acute and subchronic toxicity, reproduction toxicology]. Stenger E G, Aeppli L, Peheim E, et al. Arzneimittel-Forschung. 1970; 20 (6) : 794-9.
Publication [Experimental studies in man on hyaluronidase inhibiting effect of clofazimine]. Mathies H, Ress U. Arzneimittel-Forschung. 1970; 20 (12) : 1838-40.
Publication A new method for the manufacture of bis(4-aminophenyl)-sulfone and the anti-leprosy, anti-tuberculosis, and antibiotic activities of some new derivatives related to the drug. I. Sah P P, Peoples S A, Kwan S T, et al. Arzneimittel-Forschung. 1967; 17 (4) : 425-51.
Publication [Chemotherapy of leprosy; experimental studies on the action of three related compounds of 4, 4-diamino-diphenyl sulfon and their derivatives]. HADLER W A, ZITI L M. Arzneimittel-Forschung. 1956; 6 (9) : 534-6.